Suppr超能文献

全身 MRI 在多发性骨髓瘤治疗反应评估中的作用:临床反应与影像反应的比较。

Role of whole-body MRI for treatment response assessment in multiple myeloma: comparison between clinical response and imaging response.

机构信息

Department of Radiology and Research Institute of Radiology, Asan Image Metrics, Clinical Trial Center, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, South Korea.

Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.

出版信息

Cancer Imaging. 2020 Jan 30;20(1):14. doi: 10.1186/s40644-020-0293-6.

Abstract

BACKGROUND

Whole-body MRI (WB-MRI) including diffusion-weighted image (DWI) have been widely used in patients with multiple myeloma. However, evidence for the value of WB-MRI in the evaluation of treatment response remains sparse. Therefore, we evaluated the role of WB-MRI in the response assessment.

METHODS

In our WB-MRI registry, we searched multiple myeloma patients treated with chemotherapy who underwent both baseline and follow-up WB-MRI scans. Clinical responses were categorized as complete response (CR), partial response (PR), stable disease (SD), or progressive disease (PD), using IMWG criteria. Using RECIST 1.1, MD Anderson (MDA) criteria, and MDA-DWI criteria, imaging responses on WB-MRI were rated as CR, PR, SD, or PD by two radiologists independently. Then, discrepancy cases were resolved by consensus. Weighted Kappa analysis was performed to evaluate agreement between the imaging and clinical responses. The diagnostic accuracy of image responses in the evaluation of clinical CR, objective response (CR and PR), and PD was calculated.

RESULTS

Forty-two eligible patients were included. There was moderate agreement between imaging and clinical responses (κ = 0.54 for RECIST 1.1, κ = 0.58 for MDA criteria, κ = 0.69 for MDA-DWI criteria). WB-MRI showed excellent diagnostic accuracy in assessment of clinical PD (sensitivity 88.9%, specificity 94.7%, positive predictive value [PPV] 84.2%, negative predictive value [NPV] 96.4% in all three imaging criteria). By contrast, WB-MRI showed low accuracy in assessment of clinical CR (sensitivity 4.5%, specificity 98.1%, PPV 50.0%, NPV 71.2% in all three imaging criteria). As to the clinical objective response, the diagnostic accuracy was higher in MDA-DWI criteria than RECIST 1.1 and MDA criteria (sensitivity/specificity/PPV/NPV, 84.2%/94.4%/98.0%/65.4, 54.4%/100%/100%/40.9, and 61.4%/94.4%/97.2%/43.6%, respectively).

CONCLUSIONS

In the imaging response assessment of multiple myeloma, WB-MRI showed excellent performance in the evaluation of PD, but not in the assessment of CR or objective response. When adding DWI to imaging response criteria, diagnostic accuracy for objective response was improved and agreement between imaging and clinical responses was increased.

摘要

背景

全身磁共振成像(WB-MRI)包括弥散加权成像(DWI)已广泛应用于多发性骨髓瘤患者。然而,WB-MRI 在评估治疗反应中的价值的证据仍然很少。因此,我们评估了 WB-MRI 在反应评估中的作用。

方法

在我们的 WB-MRI 注册中心,我们搜索了接受化疗且同时进行基线和随访 WB-MRI 扫描的多发性骨髓瘤患者。使用 IMWG 标准,将临床反应分为完全缓解(CR)、部分缓解(PR)、稳定疾病(SD)或进展性疾病(PD)。使用 RECIST 1.1、MD 安德森(MDA)标准和 MDA-DWI 标准,两位放射科医生独立评估 WB-MRI 的影像学反应为 CR、PR、SD 或 PD。然后,通过共识解决差异病例。采用加权 Kappa 分析评估影像学和临床反应之间的一致性。计算图像反应在评估临床 CR、客观反应(CR 和 PR)和 PD 中的诊断准确性。

结果

纳入 42 例符合条件的患者。影像学和临床反应之间存在中度一致性(RECIST 1.1 的 Kappa 值为 0.54,MDA 标准的 Kappa 值为 0.58,MDA-DWI 标准的 Kappa 值为 0.69)。WB-MRI 在评估临床 PD 方面具有出色的诊断准确性(在所有三种影像学标准中,敏感性为 88.9%,特异性为 94.7%,阳性预测值 [PPV] 为 84.2%,阴性预测值 [NPV] 为 96.4%)。相比之下,WB-MRI 在评估临床 CR 方面的准确性较低(在所有三种影像学标准中,敏感性为 4.5%,特异性为 98.1%,PPV 为 50.0%,NPV 为 71.2%)。对于临床客观反应,MDA-DWI 标准的诊断准确性高于 RECIST 1.1 和 MDA 标准(敏感性/特异性/PPV/NPV,84.2%/94.4%/98.0%/65.4,54.4%/100%/100%/40.9 和 61.4%/94.4%/97.2%/43.6%)。

结论

在多发性骨髓瘤的影像学反应评估中,WB-MRI 在评估 PD 方面表现出色,但在评估 CR 或客观反应方面表现不佳。当将 DWI 添加到影像学反应标准中时,客观反应的诊断准确性得到提高,影像学和临床反应之间的一致性也得到提高。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/65b4/6993415/fe6ef6d20322/40644_2020_293_Fig1_HTML.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验